Short Interest Update on Anthera Pharmaceuticals (ANTH)

Anthera Pharmaceuticals (ANTH) : The short interest in Anthera Pharmaceuticals (ANTH) has increased from 4,689,870 to 4,707,055 from Jul 29, 2016, to August 15, 2016, indicating that the traders are bearish on the stock. On an average, 394,815 shares are traded daily in the stock and only 12 days are left for the shorts to cover. The short open interest is 14.1% of the total shares in the hands of the public. The shorts in the stock have gone up by 17,185 shares, which is an increase of 0.4% over the previous reading. The short interest information was released on Wednesday Aug 24th after the market close.

Anthera Pharmaceuticals (NASDAQ:ANTH): The stock opened at $3.21 on Wednesday but the bulls could not build on the opening and the stock topped out at $3.29 for the day. The stock traded down to $3.00 during the day, due to lack of any buying support eventually closed down at $3.04 with a loss of -5.59% for the day. The stock had closed at $3.22 on the previous day. The total traded volume was 610,177 shares.


In a related news, Hislop Colin, (Chief Medical Officer) of Anthera Pharmaceuticals Inc, unloaded 12,500 shares at an average price of $5.31 on November 13, 2015. The total amount of the transaction was worth $66,375, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Anthera Pharmaceuticals Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Companys primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others. The Companys second product candidate Sollpura (liprotamase) is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI) often seen in patients with cystic fibrosis and other conditions.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *